Yuichi Iwaki - MediciNova President CEO, Director
| MNOV Stock | USD 1.36 0.03 2.26% |
CEO
Dr. Yuichi Iwaki, M.D., Ph.D., is the President, Chief Executive Officer and Director of MediciNova, Inc. He is a founder of our Company and served as the Chairman of the Board of Directors from our inception in September 2000 to March 2007, becoming Executive Chairman in July 2005, Acting Chief Executive Officer as of September 2005 and President and Chief Executive Officer as of March 2006. From September 2001 until January 2007, Dr. Iwaki also served as our consultant in connection with financing transactions and business development activities. Dr. Iwaki was a member of the board of directors of Avigen, Inc. from 1994 to 2008. He holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and was Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held two professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of more than 200 peerreviewed publications and more than 40 book chapters. Dr. Iwaki was advising pharmaceutical companies and VC funds regarding research and investment strategies for over 30 years and serves on the board of directors of several biotechnology companies. since 2014.
| Age | 68 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 4275 Executive Square, La Jolla, CA, United States, 92037 |
| Phone | 858 373 1500 |
| Web | https://www.medicinova.com |
MediciNova Management Efficiency
The company has return on total asset (ROA) of (0.0881) % which means that it has lost $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1293) %, meaning that it created substantial loss on money invested by shareholders. MediciNova's management efficiency ratios could be used to measure how well MediciNova manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, MediciNova's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 4.8 M in 2024, whereas Other Assets are likely to drop slightly above 101.4 K in 2024.Similar Executives
| Found 4 records | CEO Age | ||
| Gail Boudreaux | AN2 Therapeutics | 55 | |
| Joel Ackerman | Champions Oncology | 52 | |
| Richard Cunningham | Anebulo Pharmaceuticals | 53 | |
| Ronnie MD | Champions Oncology | 58 | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0881 |
MediciNova Leadership Team
Elected by the shareholders, the MediciNova's board of directors comprises two types of representatives: MediciNova inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MediciNova. The board's role is to monitor MediciNova's management team and ensure that shareholders' interests are well served. MediciNova's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MediciNova's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason CPA, CFO Officer | ||
| Esther Boom, CFO | ||
| Kazuko Matsuda, Chief Medical Officer | ||
| Dr MBA, Chief Officer | ||
| Masatsune Okajima, Head of Japanese Office and VP | ||
| Carla Reyes, CFO | ||
| Jeffrey Himawan, Independent Chairman of the Board | ||
| Yutaka Kobayashi, Director | ||
| MD MPH, Chief Director | ||
| Yoshio Ishizaka, Director | ||
| Hideki Nagao, Director | ||
| Ryan Selhorn, CFO | ||
| Yuichi Iwaki, President CEO, Director | ||
| Yuichi MD, President, CoFounder | ||
| Geoffrey OBrien, Vice President IR Contact Officer | ||
| John CPA, Controller |
MediciNova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MediciNova a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0881 | ||||
| Operating Margin | (9.90) % | ||||
| Current Valuation | 14.86 M | ||||
| Shares Outstanding | 49.05 M | ||||
| Shares Owned By Insiders | 2.50 % | ||||
| Shares Owned By Institutions | 21.13 % | ||||
| Number Of Shares Shorted | 333.64 K | ||||
| Price To Earning | (24.69) X | ||||
| Price To Book | 1.23 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MediciNova. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for MediciNova Stock analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is MediciNova's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MediciNova. If investors know MediciNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MediciNova listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.17) | Revenue Per Share 0.02 | Return On Assets (0.09) | Return On Equity (0.13) |
The market value of MediciNova is measured differently than its book value, which is the value of MediciNova that is recorded on the company's balance sheet. Investors also form their own opinion of MediciNova's value that differs from its market value or its book value, called intrinsic value, which is MediciNova's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MediciNova's market value can be influenced by many factors that don't directly affect MediciNova's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MediciNova's value and its price as these two are different measures arrived at by different means. Investors typically determine if MediciNova is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MediciNova's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.